Additional Information

Description

Zirabev SF 25 mg/mL is a biosimilar to bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is indicated for the treatment of multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer. By blocking VEGF, Zirabev disrupts tumor angiogenesis, reducing blood supply to the tumor and inhibiting its growth and metastasis.

Administration is via intravenous infusion, with dosing dependent on the specific cancer type being treated. It is typically given in combination with chemotherapy. The infusion should be administered over a controlled duration to minimize infusion-related reactions. Premedication may be required in certain patients to reduce hypersensitivity risks. Common adverse effects include hypertension, proteinuria, epistaxis, and fatigue.

Patients receiving Zirabev require monitoring for hypertension, proteinuria, and thromboembolic events. Blood pressure should be regularly assessed, and urine protein levels should be measured periodically. The medication should be discontinued prior to elective surgery and resumed only after adequate wound healing.